Verastem, Inc. (NASDAQ:VSTM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 23, 2020, the board of directors (the “Board”) of Verastem, Inc. (the “Company”) unanimously voted to elect John Johnson as a Class I director of the Company and to serve on the nominating and corporate governance and compensation committees of the Board, effective immediately. In connection with his appointment as a director, Mr. Johnson received a stock option grant of 25,000 shares of the Company’s common stock. Mr. Johnson will be eligible to receive certain annual cash retainer fees and an annual stock option grant under the Company’s director compensation policy. Mr. Johnson also entered into a customary indemnification agreement with the Company.
A press release announcing Mr. Johnson’s appointment and other matters is filed as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
EXHIBIT INDEX
| 99.1 | Press Release issued by Verastem, Inc. on April 23, 2020 |
Verastem, Inc. Exhibit
EX-99.1 2 tm2016611d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Verastem Oncology Appoints John H. Johnson to its Board of Directors BOSTON,…
To view the full exhibit click here
About Verastem, Inc. (NASDAQ:VSTM)
Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company’s programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company’s VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company’s VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
